ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference
ObsEva SA (NASDAQ: OBSV) announced a corporate update to be presented at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ObsEva SA (NASDAQ: OBSV) announced a corporate update to be presented at the H.C. Wainwright Global Investment Conference, scheduled virtually and in Miami from May 23 – 26, 2022. The presentation will be available on-demand starting at 10:30 a.m. EST on May 24, 2022. ObsEva focuses on developing and commercializing therapies for women’s reproductive health, addressing conditions like uterine fibroids and endometriosis. Interested parties can access the webcast through the conference portal or via the company's website under the “Events Calendar” section.
Details
News Market Reaction – OBSV
The recorded move for OBSV in the trading session of this news was +5.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GENEVA, Switzerland May 16, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright Global Investment Conference, taking place virtually and in Miami, Florida from May 23 – 26, 2022.
The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 10:30 a.m. EST on Tuesday, May 24, 2022.
A webcast can be accessed here and will also be accessible under “Events Calendar” in the investors section of ObsEva’s website.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com
For further information, please contact:
CEO Office contact
Shauna Dillon
shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Katja Bührer
Katja.buhrer@obseva.com
+1 (917) 969-3438
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.